There is substantial interest in how glucagon-like peptide-1 receptor agonists (GLP-1RA) and SGLT2 (sodiumglucose cotransporter 2) inhibitors reduce cardiovascular and renal events; yet, robust mechanistic data in humans remain sparse. We conducted a narrative review of published and ongoing mechanistic clinical trials investigating the actions of SGLT2 inhibitors and GLP-1RAs to help the community appreciate the extent of ongoing work and the variety and design of such trials.
reduced major adverse cardiac events (a composite of acute myocardial infarction, stroke, or cardiovascular death), as well as heart failure (HF) hospitalization and renal end points. 5 Of note, there was no obvious effect on stroke and an unconvincing effect on myocardial infarction. 6 While there was some variability in the effect of specific agents on individual end points, it remains unclear to what extent these are true differences between drugs, the participants studied or both, or are simply a chance finding. In 2019, 2 further SGLT2 inhibitor trials demonstrated the benefit of these drugs to patients with chronic kidney disease 4 and patients with HF with reduced ejection fraction (EF), including HF with reduced EF without T2D. 7 Seven GLP-1RA mortality/morbidity trials have been published. A recent meta-analysis reported that GLP-1RAs reduce major adverse cardiac events, cardiovascular death, and all-cause mortality by around 12%, with evidence for around a 9% reduction in myocardial infarction and 16% reduction in stroke. 8 Furthermore, HF was lowered by 9% and a composite renal outcome that includes macroalbuminuria lowered by 17%. There was modest heterogeneity in results for major adverse cardiac events with Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide; ELIXA) being the main outlier. There is much more evidence of differences between drugs and also between the patients studied in the GLP-1RA trials compared with the SGLT2 inhibitor trials. 6 SGLT2 inhibitors and GLP-1RAs have been recommended in patients with diabetes mellitus and existing cardiovascular disease in all major international guidelines. 9, 10 The recent European Society of Cardiology guidelines have gone a step further and recommended that these agents should be first-line therapy (replacing metformin) in drug-naive patients with cardiovascular disease and diabetes mellitus. 11 
Mechanisms of Action and Need for Further Study
The clinical benefits for both classes of drugs cannot be explained only by effects on glucose-lowering or other established risk factors, leading many to consider novel mechanisms of action. Some clinicians may not be overly interested in understanding mechanisms provided large trials show meaningful benefits alongside evidence of safety. However, others would strongly argue that understanding mechanisms has several potential benefits such as (1) help the development of new classes of drugs in the future, (2) improved understanding of possible new applications for these drugs, and (3) lead to a better understanding of the adverse effects of drugs and how to potentially mitigate these. There is no consensus about the mechanisms explaining the action of these drugs and more work is therefore needed to elucidate these.
METHODS
We have summarized the wide range of completed and ongoing mechanistic studies in relation to the pathways under investigation, the different investigative approaches utilized, and the variety of populations targeted (Figures 1 and 2 • It remains uncertain how SGLT2 (sodium-glucose cotransporter 2) inhibitors and glucagon-like peptide-1 receptor agonists reduce cardiovascular events and multiple mechanistic studies are currently being conducted across both classes using a range of techniques and across differing populations. • SGLT2 inhibitor mechanistic trials focus on a range of pathways including those linked to hyperglycemia, hemodynamic/volume effects, cardiovascular and renal effects, and cardiac metabolism. • SGLT2 inhibitor trials are studying populations with established cardiovascular disease (including coronary artery disease and heart failure), liver disease (eg, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis), renal impairment (including postrenal transplant), obesity, and hypertension; and have enrolled patients with and without type 2 diabetes mellitus (eg, healthy, type 1 diabetes mellitus, gestational diabetes mellitus). • Glucagon-like peptide-1 receptor agonists mechanistic trials focus on weight reduction and blood pressure lowering effects, vascular, cardiac, inflammatory, and renal effects. • GLP-1RA trials are studying populations with obesity, coronary artery disease, heart failure, HIV, osteoarthritis, chronic obstructive pulmonary disease, liver disease, Alzheimer disease, Parkinson disease, schizophrenia, tobacco-dependence, alcohol-dependence, and craniopharyngioma; and have also included patients with and without type 2 diabetes mellitus (eg, healthy, prediabetes, type 1 diabetes mellitus).
Downloaded from http://ahajournals.org by on February 20, 2020 nonplacebocontrolled or active comparator), population (with diabetes mellitus versus without diabetes mellitus), and sample size. We have not included trials primarily investigating pharmacodynamics, pharmacokinetics, dosing, efficacy, safety, and cardiovascular outcomes. We have only included randomized larger (n≥40) trials of longer duration (≥3 months). We have not included trials which primarily investigate effects on glucoselowering/metabolism or other established risk factors (blood pressure lowering, weight lowering, lipid profile).
Completed Mechanistic Randomized Placebocontrolled Trials of SGLT2 Inhibitors

Cardiac Effects of SGLT2 Inhibitors in Patients With Diabetes mellitus
Of the multiple trials investigating cardiac remodeling, only one such trial has reported-EMPA-HEART (n=97), a randomized placebocontrolled parallel group trial, demonstrated a modest effect of empagliflozin on left ventricular (LV) mass on magnetic resonance imaging (MRI) in patients with T2D, stable coronary artery disease but normal EF (NCT02998970; Table 1 ). 12 
Cardiac, Biomarker, Symptom, and Fitness Effects of SGLT2 Inhibitors in Patients With and Without Diabetes Mellitus
DEFINE-HF (n=263) was a randomized placebocontrolled parallel group trial in HF (LV EF ≤40%) patients with and without T2D, showing that 12 weeks of treatment with dapagliflozin did not affect mean N-terminal pro-B-type natriuretic peptide but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status (Kansas City Cardiomyopathy Questionnaire) (NCT02653482). 13 EMPERIAL-preserved (NCT03448406; n=315) and EMPERIAL-reduced (NCT03448419; n=312) LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV(i), left ventricular end-systolic volume (indexed); LVM(i), left ventricular mass (indexed); MFR, myocardial flow reserve; MI, myocardial infarction; MPR, myocardial perfusion reserve; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAA, N acetyl-aspartate; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NT-proBNP, N-terminal pro-Btype natriuretic peptide; PADP, pulmonary artery diastolic pressure; PCOS, polycystic ovarian syndrome; PCr/ATP, phosphocreatinine/ATP; PET, positron emission tomography; PYY, Peptide-YY; Rb-82, rubidium-82; RHI, reactive hyperemia index; SPECT, single photon emission computed tomography; STEMI, ST-segment elevation myocardial infarction; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; U ACR, urinary albumin creatinine ratio; VO 2 , peak oxygen consumption; and Vv (Int/cortex), cortical interstitial fractional volume. Downloaded from http://ahajournals.org by on February 20, 2020 were randomized placebocontrolled parallel group trials in patients with HF (LV and EF >40% and ≤40%, respectively) with and without T2D, which both did not show any change from baseline to week 12 in exercise ability with empagliflozin, as measured by the 6-minute walk test. 14 
Vascular Effects of SGLT2 Inhibitors in Patients With Diabetes Mellitus
EMPA-RenalTx, a randomized placebocontrolled parallel group trial, demonstrated that patients with posttransplantation diabetes mellitus (renal transplant; n=49) on empagliflozin (vs placebo) over 24 weeks showed no between-group difference with pulse wave velocity (NCT03157414). 15 In a randomized placebocontrolled parallel group trial of 40 patients with type 1 diabetes mellitus, empagliflozin on top of metformin over 12 weeks improved flow-mediated dilatation, reactive hyperemia index, pulse wave velocity, and carotid artery stiffness (NCT03639545). 16 
Liver Effects of SGLT2 Inhibitors in Patients With Diabetes Mellitus
The randomized placebocontrolled parallel group EFFECT II trial of 84 T2D patients with nonalcoholic fatty liver disease showed that, over 12 weeks, dapagliflozin and omega-3 carboxylic acids significantly reduced liver fat content measured on MRI, while dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and fibroblast growth factor 21 (NCT02279407). 17 In 56 T2D patients, a randomized placebocontrolled parallel group trial showed that canagliflozin (vs placebo) did not change intrahepatic triglyceride measured on magnetic resonance spectroscopy (NCT02009488). 18 Ach, acetylcholine; ADAS-cog, Alzheimer's Disease Assessment Scale; AF, atrial fibrillation; AGE, advanced glycation end product; AHI, apnea-hypopnea index; AI, augmentation index; ASCVD, atherosclerotic cardiovascular disease; BOLD, blood-oxygen-level-dependent; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCN, confirmed clinical neuropathy; CFR, coronary flow reserve; CMR, cardiac magnetic resonance; CT, computed tomography; CV, cardiovascular; DCE, dynamic contrast-enhanced; DEXA, dual energy X-ray absorptiometry; DSE, dobutamine stress echocardiography; dysfx, dysfunction; E, early transmitral peak flow rate; Ea, early peak mitral annular septal tissue velocity; EAT, epicardial adipose tissue; EEG, electroencephalography; EMG, electromyography; EPC, endothelial progenitor cell; FAI, free androgen index; FBF, forearm blood flow; FCR, food-cue reactivity; FDG, fluorodeoxyglucose; FMD, flow-mediated dilatation; fMRI, functional magnetic resonance imaging; fx, function; GFR, glomerular filtration rate; HR, heart rate; IGT, impaired glucose tolerance; IMT, intimamedia thickness; KISS, kidney injury summary score; KOOS, Knee injury and Osteoarthritis Outcome Score; LA, left atrium; LFRI, longitudinal functional reserve index; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MISS, myocardial injury summary score; MRE, magnetic resonance elastography; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NSTEMI, non-ST segment elevation myocardial infarction; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor 1; PET, positron emission tomography; PWV, pulse wave velocity; rCBF, regional cerebral blood flow; RHI, reactive hyperemia index; RHR, resting heart rate; rRNA, ribosomal RNA; SF-36, short form health survey; STEMI, ST-segment elevation myocardial infarction; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TBR, target-to-background ratio; TDI, Transition Dyspnea Index; U ACR, urinary albumin creatinine ratio; and UAER, urinary albumin excretion rate. Downloaded from http://ahajournals.org by on February 20, 2020 
Liver Effects of SGLT2 Inhibitors in Patients Without Diabetes Mellitus
The randomized placebocontrolled parallel group Dapalost trial of 50 nondiabetic or prediabetic patients showed that although the combination of dapagliflozin and exenatide reduced liver fat (as measured on MRI) from baseline at 24 weeks, this was not significantly different compared with placebo (NCT02313220). 19 
Completed Mechanistic Randomized Nonplacebocontrolled Trials of SGLT2 Inhibitors
Vascular Effects of SGLT2 Inhibitors in Patients Without Diabetes Mellitus
In a randomized controlled parallel group comparison of 3 months treatment with empagliflozin or metformin in 40 women with polycystic ovarian syndrome (PCOS), without T2D and without prediabetes, SGLT2 inhibitor therapy had no effect on reactive hyperemia index or augmentation index assessed with EndoPAT (NCT03008551). 20
Renal Effects of SGLT2 Inhibitors in Patients With Diabetes Mellitus
In the randomized controlled parallel group RED study of T2D patients (n=44) comparing dapagliflozin or gliclazide over 12 weeks, dapagliflozin reduced measured glomerular filtration rate and reduced filtration fraction without increased renal vascular resistance as measured by insulin-and para-aminohippurate clearance (NCT02682563). 21 
Liver Effects of SGLT2 Inhibitors in Patients With Diabetes Mellitus
The randomized parallel group E-LIFT study of empagliflozin versus standard care showed that 50 patients with nonalcoholic fatty liver disease (NAFLD) with T2D on empagliflozin over 3 months had reduced liver fat and improved alanine transferase levels on MRI (NCT02686476). 22 
Completed Mechanistic Randomized Placebocontrolled Trials of GLP-1RAs
Cardiovascular Effects of GLP-1RAs in Patients With Diabetes Mellitus
The randomized placebocontrolled parallel group MAGNA VICTORIA trial of 50 patients with T2D showed that liraglutide over 26 weeks reduced early LV diastolic filling and LV filling pressure and reduced LV systolic function on cardiac MRI (NCT01761318; Table 3 ). 23 In 47 patients with T2D of South Asian descent, with or without ischemic heart disease, randomly assigned to 26-week treatment with liraglutide or placebo, liraglutide did not affect LV diastolic and systolic function, aortic stiffness, myocardial triglyceride content, or extracellular volume, measured NCT indicates www.Clinicaltrials.gov registration number. N indicates number randomized. 6MWT indicates 6-minute walk test; BMI, body mass index; BNP, B-type natriuretic peptide; CHQ-SAS, Chronic Heart Failure Questionnaire Self-Administered Standardized Format; CV, cardiovascular; DEXA, dual energy X-ray absorptiometry; EF, ejection fraction; FGF21, fibroblast growth factor 21; FMD, flow-mediated dilatation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; MI, myocardial infarction; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, nonalcoholic fatty liver disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OM-3CA, omega-3 (n-3) carboxylic acids; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity; PWV, pulse wave velocity; RHI, reactive hyperemia index; SGLT2, sodium-glucose cotransporter 2; T1D, type 1 diabetes mellitus; and T2D, type 2 diabetes mellitus. *Primary outcome. by MRI (NCT02660047). 24 In a 12-week placebocontrolled parallel group trial in 49 patients with T2D, liraglutide did not impact endothelium-dependent vasodilation (NCT00620282). 25 AddHope2 was a randomized placebocontrolled crossover study over 12 weeks (with a 2 week washout period) in 41 patients with T2D with stable coronary disease, which showed that liraglutide did not change LV EF at rest, at low stress, at peak stress, or at recovery, measured by dobutamine stress echocardiography (NCT01595789). 26 This trial also showed no change in wall motion score index at any stress levels and no change in global longitudinal strain or global longitudinal strain rate at rest.
Cardiovascular Effects of GLP-1RAs in Patients With and Without Diabetes Mellitus
Both the randomized placebocontrolled parallel group FIGHT study of 300 patients recently hospitalized with HF (with reduced LV EF; NCT01800968), with or without T2D, and the randomized placebocontrolled parallel group LIVE study (NCT01472640) of 241 patients with HF (EF ≤45%), with or without T2D, found that liraglutide (vs placebo), over 180 days and 24 weeks, respectively, did not change LV EF on echocardiogram. 27, 28 Furthermore, in LIVE, liraglutide was associated with increased heart rate and more serious cardiac adverse events. 28 In the randomized placebocontrolled parallel group POSTCON II trial of patients with ST-segment elevation myocardial infarction (n=148 with MRI data), exenatide over 3 months reduced MRImeasured final infarct size in patients with a short system delay (≤132 minutes) but not in those with a long system delay (>132 minutes; NCT00835848). 29 A randomized placebocontrolled parallel group trial of 96 ST-segment elevation myocardial infarction patients showed that liraglutide improved myocardial salvage and infarct size on MRI after 3 months (NCT02001363). 30 EMPIRE randomized 116 ST-segment elevation myocardial infarction patients to exenatide or placebo in parallel groups and showed that at 6 months (n=58), exenatide reduced E/e' with improved strain parameters, measured by conventional and speckle tracking echocardiography (NCT01580514). 31 
Cardiovascular Effects of GLP-1RAs in Patients Without Diabetes Mellitus
EXAMI was a randomized placebocontrolled parallel group trial of 191 nondiabetic patients with ST-segment elevation myocardial infarction and showed that exenatide over 4 months did not change myocardial infarct size on MRI (NCT01254123). 32 Forty five nondiabetic patients with schizophrenia were randomized to exenatide or placebo in parallel groups in the TAO trial, which showed that exenatide reduced pulse wave velocity at 3 months (NCT01794429). 33 
Renal Effects of GLP-1RAs in Patients With Diabetes Mellitus
SAFEGUARD was a randomized placebocontrolled parallel group trial of 56 patients with T2D on exenatide, showing no change in effective renal plasma flow, measured by para-aminohippurate clearance, over 12 weeks (NCT01744236). 34 
Liver and Gallbladder Effects of GLP-1RAs in Patients With Diabetes Mellitus
SAFEGUARD randomized 56 T2D patients to liraglutide versus sitagliptin versus placebo in parallel groups, and did not find any change in gallbladder volume, hepatic steatosis or fibrosis, after 12 weeks of treatment (NCT01744236). 35, 36 The randomized placebocontrolled parallel group LEAN study of 52 T2D patients with nonalcoholic steatohepatitis showed that liraglutide over 48 weeks led to histological resolution of nonalcoholic steatohepatitis (NCT01237119). 37 
Liver and Gallbladder Effects of GLP-1RAs in Patients With or Without Diabetes Mellitus
A randomized placebocontrolled study of 40 patients with or without T2D showed that liraglutide delayed gastric emptying on scintigraphy, at 5 and 16 weeks of treatment (NCT02647944). 38 
Liver, Gallbladder, Metabolic, and Biomarker Effects of GLP-1RAs in Patients Without Diabetes Mellitus
The LIPT randomized placebocontrolled trial of 72 patients with PCOS without diabetes mellitus showed that liraglutide for 26 weeks reduced liver fat content, reduced visceral adipose tissue, and reduced the prevalence of NAFLD (NCT02073929). 39 Furthermore, LIPT showed improved bleeding regularity, improved markers of ovarian function, and reduced midregional-pro-atrial natriuretic peptide. 40, 41 A randomized placebocontrolled trial of 52 nondiabetic overweight/obese patients showed that liraglutide over 12 weeks was not associated with any change in gallbladder EF measured on ultrasonography (NCT02717858). 42 Dapalost randomized 50 patients who are nondiabetic or prediabetic to exenatide/dapagliflozin versus placebo over 24 weeks, showing no between-group difference on liver fat on MRI (NCT02313220). 19 
Lung Effects of GLP-1RAs in Patients Without Diabetes Mellitus
The randomized placebocontrolled SCALE trial of 359 nondiabetic patients with moderate-severe obstructive sleep apnea showed that liraglutide over 32 weeks reduced apnea-hypopnea index (NCT01557166). 43 
Neurological and Anti-Inflammatory Effects of GLP-1RAs in Patients With and Without Diabetes Mellitus
GLIP1 randomized 120 patients with out of hospital cardiac arrest, with or without diabetes mellitus, to exenatide or placebo, and found that there was no change to neurological function at 30, 90, and 180 days (NCT02442791). 44 TODINELI was a randomized placebocontrolled trial of 48 patients with type 1 diabetes mellitus, showing that liraglutide over 26 weeks reduced interleukin-6, while neuronal function was unaltered (NCT02138045). 45 
Neurological Effects of GLP-1RAs in Patients Without Diabetes Mellitus
GREAT randomized 103 prediabetic patients with schizophrenia, schizotypal disorder, or paranoid psychosis to liraglutide or placebo and showed that there was no change in measures of psychopathology at 1 year (NCT01845259). 46 Sixty two nondiabetic patients with Parkinson's disease were randomized to exenatide or placebo in EXENATIDE-PD, and over 60 weeks, exenatide had positive effects on practically defined off-medication motor scores, which were sustained beyond the period of exposure (NCT01971242). 47 In TAO, a randomized placebocontrolled trial of 45 nondiabetic patients with schizophrenia, exenatide for 3 months (n=40) did not change cognition or psychosocial function (NCT01794429). 48 
Completed Mechanistic Randomized Nonplacebocontrolled Trials of GLP-1RAs
Cardiovascular Effects of GLP-1RAs in Patients With Diabetes Mellitus
AWARD-6 randomized 599 patients with T2Ds to dulaglutide versus liraglutide over 26 weeks and did not find any change in PR interval on ECG (NCT01624259). 49 Sixty two patients with T2D with HF (EF ≤50% or diastolic function) were randomized to liraglutide or glimepiride over 18 weeks, showing no change in longitudinal fractional reserve index on exercise tissue Doppler echocardiography (NCT01425580; Table 4 ). 50 In a randomized trial of 60 patients with newly diagnosed and treatment-naïve T2D randomized to liraglutide or metformin, 6-month treatment with liraglutide reduced arterial stiffness, LV myocardial strain, LV twisting and untwisting and N-terminal pro-B-type natriuretic peptide by reducing oxidative stress, while these measured markers were unchanged in the metformin group (except for improved flow mediated dilation) (NCT03010683). 51 In a randomized trial of 44 T2D patients on metformin, the addition of liraglutide improves several cardiovascular risk markers, but there was no change for arterial stiffness parameters (NCT01208012). 52
Cardiovascular Effects of GLP-1RAs in Patients Without Diabetes Mellitus
In 50 patients with impaired glucose tolerance (but without diabetes mellitus) and abdominal obesity, randomized to exenatide versus metformin for 3 months, exenatide therapy had similar effects of microvascular endothelial function as metformin (NCT00546728). 53 
Metabolic and Liver Effects of GLP-1RAs in Patients With Diabetes Mellitus
In 93 patients with T2D with NAFLD, randomized to liraglutide versus metformin versus gliclazide, over 168 days follow-up, reductions in intrahepatic fat were greater with liraglutide and metformin than with gliclazide (NCT03068065). 54 In addition, compared with gliclazide, liraglutide and metformin monotherapies reduced body fat mass measured on dual energy X-ray absorptiometry. 55 In the LIGHT-ON randomized active comparator trial, 75 patients with T2D with simple liver steatosis randomized to liraglutide versus insulin glargine versus sitagliptin over 26 weeks, both liraglutide and sitagliptin reduced intrahepatic lipid, and reduced visceral adipose tissue measured by MRI (NCT02147925). 56 
Metabolic Effects of GLP-1RAs in Patients Without Diabetes Mellitus
In a randomized parallel group trial of 183 patients with impaired glucose regulation and PCOS, randomized to 3 groups (exenatide versus metformin versus exenatide+metformin), over 12 weeks, there was reduced testosterone and free androgen index in all 3 groups (although there was no reported betweengroup P value) (NCT03352869). 57
Neurological Effects of GLP-1RAs in Patients With Diabetes Mellitus
In 46 patients with T2D with diabetic peripheral neuropathy, randomized in parallel groups to exenatide versus insulin glargine over 18 months, there was no change in confirmed clinical neuropathy, intraepidermal nerve fiber density, or measures of cardiac autonomic neuropathy (NCT00855439). 58 Arterioscler Thromb Vasc Biol. 2020;40:00-00. DOI: 10.1161/ATVBAHA.119.311904 
Neurological Effects of GLP-1RAs in Patients Without Diabetes Mellitus
In 45 nondiabetic patients with idiopathic Parkinson's disease of moderate severity, randomized to exenatide versus controls in parallel groups, over 12 and 14 months (after 2-month washout), the exenatide group had clinically relevant improvements in Parkinson's disease across motor and cognitive measures, compared with the control group (NCT01174810). 59 A randomized parallel group trial of 44 nondiabetic obese subclinical binge eating participants randomized to liraglutide or control groups, showed that over 12 weeks, liraglutide patients were less likely to binge eat (NCT01739049). 60 
Ongoing Mechanistic Trials of SGLT2 Inhibitors
The wealth of ongoing SGLT2 inhibitor mechanistic trials broadly place an emphasis on investigating (1) NCT indicates www.Clinicaltrials.gov registration number. N indicates number randomized. ADMA indicates asymmetrical dimethylarginine; AIx, augmentation index; BMI, body mass index; CAD, coronary artery disease; CFR, coronary flow reserve; DEXA, dual-energy X-ray absorptiometry; EAT, epicardial adipose tissue; EF, ejection fraction; EndoPAT, Peripheral Arterial Tone; FMD, flow-mediated dilatation; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR, heart rate; HRV, heart rate variability; hs-CRP, high-sensitivity C-reactive protein; IDEAL IQ, iterative decomposition of water and fat with echo asymmetry and least-squares estimation; IENFD, intraepidermal nerve fiber density; IGT, impaired glucose tolerance; LAD, left anterior descending; LFRI, longitudinal functional reserve index; LV, left ventricular; MCP-1, monocyte chemotactic protein 1; MRI, magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OGTT, oral glucose tolerance test; PAI-1, plasminogen activator inhibitor 1; PBR, perfused boundary region; PDFF, proton density fat fraction; PWV, pulse wave velocity; SAT, subcutaneous adipose tissue; T2D, type 2 diabetes mellitus; TDE, tissue Doppler echocardiography; UPDRS, Unified Parkinson's Disease Rating Scale; VAT, visceral adipose tissue; and VCAM, vascular cell adhesion molecule. *Primary outcome. There are also studies of body composition, tissue sodium and water content, muscle mitochondrial function, as well as hepatic and pancreatic fat with techniques including dual energy X-ray absorptiometry and magnetic resonance spectroscopy. 3. Renal-glomerular filtration, renal tubular function, and kidney perfusion are being explored with MRI, various radionuclide imaging investigations, measurement of biomarkers in blood and urine and renal biopsy.
Ongoing Mechanistic Trials of SGLT2 Inhibitors in Patients Without Diabetes Mellitus
In addition to patients with T2D, studies are also being conducted in healthy volunteers, individuals with prediabetes, and patients with a variety of other conditions including type 1 diabetes mellitus, posttransplantation diabetes mellitus (postrenal transplant), NAFLD/nonalcoholic steatohepatitis, and PCOS.
Ongoing Mechanistic Trials of GLP-1RAs
Trials with GLP-1RAs are investigating mechanisms relating to (1) fat/weight/appetite reduction, (2) cardiac structure and function, and (3) vascular function (Table IIA through IIJ in the online-only Data Supplement).
1. Appetite/weight studies include MRI of the brain. Dual energy X-ray absorptiometry, computed tomography, MRI, and magnetic resonance spectroscopy are assessing body composition, body fat, and liver fat. Scintigraphy is being utilized to study gastric emptying. 2. Cardiac studies include patients with coronary artery disease and HF with preserved as well as reduced EF. The techniques employed include echocardiography, MRI, and magnetic resonance spectroscopy. 3. Vascular (central and peripheral) studies including assessment of endothelial function, arterial stiffness, and evaluation of the carotid arteries. Common vascular measures include flow-mediated dilatation, pulse wave velocity, and carotid intima medial thickness. Positron emission tomography/computed tomography is also being used to assess vascular inflammation and coronary artery calcium score.
Ongoing Mechanistic Trials of GLP-1RAs in Patients Without Diabetes Mellitus
GLP-1 RAs are also being studied in patients other than those with T2D, including individuals with obesity and after bariatric surgery, as well as people with chronic obstructive pulmonary disease, PCOS, NAFLD/nonalcoholic steatohepatitis, osteoarthritis, HIV, Alzheimer's disease, Parkinson's disease, schizophrenia, tobacco dependence, alcohol dependence, and craniopharyngioma.
Two Exemplar Trials
We detail and discuss 2 mechanistic trials investigating an SGLT2 inhibitor and a GLP-1RA, respectively-these prospective randomized clinical trials employ state-of-the-art imaging techniques, which investigate multiple organ systems and different vascular beds, over a moderate length of time.
SUGAR-DM-HF
Empagliflozin in HF With Reduced EF A randomized, double blind, placebocontrolled investigation of the effects of empagliflozin on cardiovascular, renal, and metabolic measures over 36 weeks in 105 patients with HF with reduced EF. 61 A multicenter study recruiting from 15 hospital sites in the West of Scotland. The key inclusion criteria are HF (LV EF ≤40%, New York Heart Association class II-IV), T2D (glycated hemoglobin ≤97 mmol/mol), or prediabetes (glycated hemoglobin, 39-47 mmol/mol), age ≥18 years and with an estimated glomerular filtration rate ≥30 mL/minute per 1.73 m2. It is due to report in late 2020. The co-primary outcomes are LV end-systolic volume index and LV global longitudinal strain, both measured using cardiac MRI. Secondary outcomes include microvascular perfusion (cardio-renal) and extracellular volume fraction, both measured using MRI, quality of life score (Kansas City Cardiomyopathy Questionnaire), and exercise capacity (6-minute walk test). Study medication is discontinued at week 36 and patients return for MRI at week 40-this will establish whether structural remodeling occurs as opposed to a diuretic or hemodynamic effect.
LIRAFLAME Liraglutide and Vascular Inflammation
A randomized, double blind, placebocontrolled investigation of the effects of liraglutide on vascular inflammation over 26 weeks, in 100 participants with T2D. 62 The key inclusion criteria are age >50 years with a glycated hemoglobin ≥48 mmol/mol, estimated glomerular filtration rate ≥30 mL/minute per 1.73 m2 and on stable glucose-lowering medication. The primary outcomes are change in vascular inflammation (as measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography). Secondary outcomes are change in endothelial function (EndoPAT, sublingual glycocalyx measurement), coronary artery calcium score and carotid intima media thickness (ultrasound). Other outcome measures include autonomic nervous system function (cardiovascular autonomic neuropathy indices). These 2 trials give a snapshot of the types of techniques being used to investigate mechanistic pathways but of course, many other techniques are being used in a variety of studies highlighted in the tables.
CONCLUSIONS
In summary, recent outcome trials have revealed 2 classes of drugs which not only reduce blood glucose but also reduce clinical events. These drugs are now recommended by major guideline changes. We remain almost totally ignorant on their mechanisms of benefit. A plethora of research activity is underway to determine mechanisms of action across key areas of interest, as we have carefully summarized in this review. Very few trials are investigating the mechanism in those without diabetes mellitus. We think our list of trials will help many researchers in the field and will help inform better trial designs in the future. Over the next 1 to 4, years many of these studies will report. Hopefully, these new studies will allow us to better understand how SGLT2 inhibitors and GLP-1RAs reduce hard outcomes.
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